William Blair analyst Myles Minter has reiterated their neutral stance on MRNA stock, giving a Hold rating on February 3.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter has given his Hold rating due to a combination of factors related to Moderna’s flu franchise outlook and regulatory risk. The FDA’s refusal to file letter for the mRNA‑1010 flu vaccine, based on concerns that the Phase III control arm did not match the prevailing standard of care in the U.S., materially weakens confidence in the program without directly questioning safety or efficacy.
This setback also casts doubt on the U.S. approval pathway and revenue potential for the combo flu/COVID candidate mRNA‑1083, which had been expected to help restore growth in the company’s COVID vaccine business and support breakeven targets around 2028. With key U.S. flu-related revenues now less certain and the overall financial model under review ahead of upcoming earnings, Minter maintains a neutral stance and reiterates a Market Perform (Hold) view on the shares.
In another report released on February 3, TD Cowen also maintained a Hold rating on the stock with a $40.00 price target.